
Join to view full profile
Seattle Cancer Care Alliance - Issaquah1740 NW Maple Street, Suite 211Issaquah, WA 98027
Phone+1 425-392-2551
Fax+1 425-392-8827
Dr. Lukas is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2008 - 2009
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2005 - 2007
University of WashingtonResidency, Internal Medicine, 2002 - 2005
Drexel University College of MedicineClass of 2002
Certifications & Licensure
CA State Medical License 2005 - Present
WA State Medical License 2002 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Start of enrollment: 2013 May 21
- BGJ398 for Patients With Tumors With FGFR Genetic Alterations Start of enrollment: 2014 Jul 24
Publications & Presentations
PubMed
- 32 citationsSubgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressin...R. Connor Chick, G. Travis Clifton, Diane F. Hale, Timothy J. Vreeland, Annelies T. Hickerson
Clinical Immunology. 2021-01-22 - 71 citationsResults of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast ...G. Travis Clifton, Diane F. Hale, Timothy J. Vreeland, Annelies T. Hickerson, Jennifer K. Litton
Clinical Cancer Research. 2020-06-01 - 15 citationsInitial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer p...G. Travis Clifton, Kaitlin M. Peace, Jarrod P. Holmes, Timothy J. Vreeland, Diane F. Hale
Clinical Immunology. 2019-04-01
Press Mentions
Seattle Cancer Care Alliance Welcomed into Issaquah with Ribbon CuttingJuly 18th, 2019
Professional Memberships
- Member
Other Languages
- Farsi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









